How Healthy Adults Respond to the Nasal Flu Vaccine

This study is looking at how your immune system in the nose responds after you receive the FluMist nasal flu vaccine. FluMist is an FDA-approved flu vaccine given as a nasal spray. We are enrolling healthy adults aged 18 to 65 who do not smoke, have no chronic medical conditions, and have not recently received a flu vaccine. The main goal is to see how your nasal immune response changes from before vaccination to four days after receiving FluMist. This study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design: This is an interventional study with 20 healthy adult participants. It is designed to observe how the body responds to the FluMist vaccine.
What's involved: You would have three study visits over about one week. These visits include screening, giving consent, receiving the FluMist vaccine, and having nasal swabs and a gentle saline nasal wash collected.
Compensation: Not stated in the trial record.
Follow-up: Your nasal immune response will be measured from before vaccination through 4 days after vaccination.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

How Healthy Adults Respond to the Nasal Flu Vaccine

Not Yet Recruiting

PHASE4Ages 18–65InterventionalBasic science

University of Alabama at Birmingham

~20 participants

Updated 2026-07-24 on ClinicalTrials.gov

What's tested:FluMist (Live Attenuated Influenza Vaccine)

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in Nasal Mucosal Immune Response Following FluMist Vaccination

Measured over Baseline through 4 days post-vaccination

Conditions

Mucosal Immune Response to Influenza Vaccination

Where it's being run

1 sites across 1 states

Alabama1

Study leadership

Kevin S Harrod, PhD · PRINCIPAL_INVESTIGATOR · UAB All Study (Central)

Who to contact

Shanna H Graves, AAS

[email protected]

205-975-2845

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Healthy adults aged 18 to 65 years

Non-smokers (no smoking or vaping within the past 6 months)

No chronic lung disease or significant chronic medical conditions

No current or recent (within 1 month) upper or lower respiratory infection

Able and willing to provide informed consent

Have not received the current seasonal influenza vaccine

Able to comply with study procedures and follow-up visits

Exclusion

Age under 18 or over 65 years

Pregnancy or breastfeeding

Prisoners

Non-English speaking individuals

Immunocompromised individuals (including HIV/AIDS, immunosuppressive therapy, chemotherapy, or primary immunodeficiency)

Chronic medical conditions including asthma, chronic lung, liver, kidney, neurologic, hematologic, metabolic, or significant cardiovascular disease (except isolated hypertension)

History of chronic sinusitis or significant nasal allergies requiring frequent or daily treatment

Acute moderate or severe illness at time of enrollment, with or without fever

Receipt of influenza vaccine during the current season or within the past 2 weeks

Receipt of another live vaccine within 4 weeks prior to enrollment or planned during study period

Use of influenza antiviral medications (e.g., oseltamivir, zanamivir) within 48 hours prior to vaccination or planned use within 14 days after vaccination

History of severe allergic reaction to influenza vaccine or any component of FluMist (including egg allergy if applicable)

History of Guillain-Barré syndrome following influenza vaccination

Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results

What this trial measures

Change in Nasal Mucosal Immune Response Following FluMist VaccinationBaseline through 4 days post-vaccination
This outcome measure evaluates changes in the nasal mucosal immune and epithelial response following administration of the intranasal live attenuated influenza vaccine (FluMist). Nasal swab and nasal wash samples will be collected at baseline (pre-vaccination) and at approximately 2 and 4 days post-vaccination. Samples will be analyzed using single-cell RNA sequencing, proteomics, and RT-qPCR to assess changes in immune cell populations, gene expression profiles, protein expression, and viral activity over time.

Trialytics